Chronic Pruritus Therapeutics Market Report 2026

The chronic pruritus therapeutics market size has grown strongly in recent years. It will grow from $10.91 billion in 2025 to $11.7 billion in 2026 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to increasing prevalence of chronic dermatological conditions, wider use of topical corticosteroids, improved diagnostic differentiation of pruritus causes, growth in dermatology specialist consultations, increased availability of antihistamine therapies.

The chronic pruritus therapeutics market size is expected to see strong growth in the next few years. It will grow to $15.33 billion in 2030 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to increasing biologic drug approvals, rising investment in dermatology research pipelines, growing focus on immune-mediated itch mechanisms, expansion of online pharmacy access, increasing patient demand for long-term relief solutions. Major trends in the forecast period include increasing adoption of targeted biologic therapies, rising focus on personalized pruritus treatment approaches, growing development of novel anti-itch molecules, expansion of combination therapy protocols, enhanced emphasis on long-term symptom management.

Rising healthcare expenditure is expected to drive the growth of the chronic pruritus therapeutics market in the coming years. Healthcare expenditure refers to the total financial resources spent by individuals, organizations, or governments on the prevention, treatment, and management of health conditions. Healthcare spending is increasing due to advancements in medical technology, as new diagnostic tools, treatments, and innovative therapies often involve higher costs, resulting in greater overall healthcare expenditure. Increased healthcare spending supports chronic pruritus therapeutics by improving patient access to dermatology services, enabling the adoption of advanced treatment options, and encouraging higher investment in innovative therapies. For instance, in December 2024, according to the Centers for Medicare and Medicaid Services, a US-based agency responsible for administering Medicare and Medicaid programs, US healthcare expenditures rose by 7.5% in 2023, reaching $4.9 trillion, or approximately $14,570 per person. Therefore, rising healthcare expenditure is contributing to the growth of the chronic pruritus therapeutics market.

Major companies operating in the chronic pruritus therapeutics market are focusing on the development of innovative formulations such as intravenous injections to improve treatment effectiveness and deliver faster symptom relief. Intravenous injection therapies help manage pruritus by administering medications, including antihistamines or corticosteroids, directly into the bloodstream to rapidly reduce itching and inflammation. For example, in September 2023, Cara Therapeutics Inc., a US-based therapeutics company, announced that its partner, Maruishi Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, received approval from Japan’s Ministry of Health, Labour and Welfare for the Korsuva IV injection syringe for the treatment of pruritus in hemodialysis patients. This approval was supported by positive Phase 3 clinical trial results conducted by Maruishi in collaboration with Kissei Pharmaceutical Co. Ltd., demonstrating significant improvements in itching scores compared to placebo and good tolerability among patients. The approval also triggered a $1.5 million milestone payment to Cara Therapeutics under the terms of its licensing agreement with Maruishi.

In May 2024, Incyte Corporation, a US-based biopharmaceutical company, acquired Escient Pharmaceuticals for $750 million. Through this acquisition, Incyte seeks to strengthen its inflammation and autoimmunity pipeline by incorporating innovative therapies targeting severe inflammatory diseases. Escient Pharmaceuticals Inc. is a US-based biotechnology company focused on developing therapeutics for uremic pruritus.

Major companies operating in the chronic pruritus therapeutics market are Pfizer Incorporated, AbbVie Inc., Sanofi S.A., Novartis Aktiengesellschaft, GlaxoSmithKline plc, CSL Behring LLC, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Incyte Corporation, Cipla Limited, Sumitomo Pharma Co. Ltd., Mallinckrodt Pharmaceuticals plc, Kissei Pharmaceutical Co. Ltd., Asana BioSciences LLC, Vanda Pharmaceuticals Inc., Dermavant Sciences Inc., Galderma Laboratories L.P., Cara Therapeutics Inc., Avior Bio Inc., Trevi Therapeutics Inc.

North America was the largest region in the chronic pruritus therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic pruritus therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chronic pruritus therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the chronic pruritus therapeutics market by increasing costs of imported active pharmaceutical ingredients, biologic compounds, and specialized manufacturing inputs used in advanced dermatology treatments. North America and Europe are most affected due to dependence on cross-border pharmaceutical supply chains, while Asia-Pacific faces cost pressures in biologic drug production and export. These tariffs are raising development and manufacturing costs and influencing pricing strategies. However, they are also encouraging regional drug manufacturing, local sourcing of raw materials, and increased investment in domestic pharmaceutical production capabilities.

The chronic pruritus therapeutics market research report is one of a series of new reports that provides chronic pruritus therapeutics market statistics, including chronic pruritus therapeutics industry global market size, regional shares, competitors with a chronic pruritus therapeutics market share, detailed chronic pruritus therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the chronic pruritus therapeutics industry. This chronic pruritus therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Chronic pruritus therapy involves treatments designed to manage or relieve persistent itching that continues for six weeks or longer. Management of chronic pruritus typically includes a combination of therapies tailored to the underlying cause, with treatment approaches adjusted based on the patient’s response.

The primary product types used in chronic pruritus therapeutics include corticosteroids, antihistamines, local anesthetics, counterirritants, immunosuppressants, calcineurin inhibitors, and other product types. Corticosteroids are medications that help reduce inflammation and itching by suppressing immune system activity, making them effective for treating chronic pruritus and inflammatory skin disorders. These products are used to manage conditions such as atopic dermatitis, allergic contact dermatitis, urticaria, and other related diseases. They are distributed through multiple channels, including hospital pharmacies, drug stores and retail pharmacies, and online providers.

The chronic pruritus therapeutics market consists of sales of capsaicin creams, jak inhibitors, systemic therapies, phototherapy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.